ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2012. World Malaria Report 2012. Available at: http://www.who.int/malaria/publications/world_malaria_report_2012/en/. Accessed June 6, 2013.
-
2.
Armed Forces Health Surveillance Center, 2013. Update: malaria, U.S. Armed Forces, 2012. MSMR 20: 2–5.
-
3.
Armed Forces Health Surveillance Center, 2011. Update: malaria, U.S. Armed Forces, 2010. MSMR 18: 2–6.
-
4.
Department of Defense, 2010. USCENTCOM 051122Z March 2010. MOD Ten to USCENTCOM Individual Protection and Individual-Unit Deployment Policy. [Superseded by MOD Eleven and no longer publically available].
-
5.
Department of the Army, 2013. Department of the Army Personnel Policy Guidance for Overseas Contingency Operations. Available at: http://www.armyg1.army.mil/MilitaryPersonnel/PPG/PPG_17-May-2013.pdf. Accessed June 6, 2013.
-
6.
Newton JA Jr, Schnepf GA, Wallace MR, Lobel HO, Kennedy CA, Oldfield EC III, 1994. Malaria in US Marines returning from Somalia. JAMA 272: 397–399.
-
7.
Kotwal RS, Wenzel RB, Sterling RA, Porter WD, Jordan NN, Petruccelli BP, 2005. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 293: 212–216.
-
8.
Brisson M, Brisson P, 2012. Compliance with antimalaria chemoprophylaxis in a combat zone. Am J Trop Med Hyg 86: 587–590.
-
9.
Whitman TJ, Coyne PE, Magill AJ, Blazes DL, Green MD, Milhous WK, Burgess TH, Freilich D, Tasker SA, Azar RG, Endy TP, Clagett CD, Deye GA, Shanks GD, Martin GJ, 2010. An outbreak of Plasmodium falciparum malaria in U.S. Marines deployed to Liberia. Am J Trop Med Hyg 83: 258–265.
-
10.
Shaha DP, Pacha LA, Garges EC, Scoville SL, Mancuso JD, 2013. Confirmed malaria cases among active component U.S. Army personnel, January–September 2012. MSMR 20: 6–9.
-
11.
Keene DD, Tong JL, Roughton S, Fadden SJ, 2012. Anti-malarial chemoprophylaxis following evacuation from Afghanistan. J R Army Med Corps 158: 38–40.
-
12.
Penn-Barwell J, Pengelly S, 2008. Audit of prescription of anti-malarial prophylaxis to patients admitted to Royal Centre for Defence Medicine (RCDM) following evacuation from Afghanistan. J R Nav Med Serv 94: 112–114.
-
13.
Tribble DR, Conger NG, Fraser S, Gleeson TD, Wilkins K, Antonille T, Weintrob A, Ganesan A, Gaskins LJ, Li P, Grandits G, Landrum ML, Hospenthal DR, Millar EV, Blackbourne LH, Dunne JR, Craft D, Mende K, Wortmann GW, Herlihy R, McDonald J, Murray CK, 2011. Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study. J Trauma 71: S33–S42.
-
14.
Eastridge BJ, Jenkins D, Flaherty S, Schiller H, Holcomb JB, 2006. Trauma system development in a theater of war: experiences from Operation Iraqi Freedom and Operation Enduring Freedom. J Trauma 61: 1366–1372, discussion 1372–1373.
-
15.
Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duelm F, Hospenthal DR, 2006. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. Mil Med 171: 905–907.
-
16.
Nevin RL, 2010. Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007. Pharmacoepidemiol Drug Saf 19: 206–210.
-
17.
Vento TJ, Calvano TP, Cole DW, Mende K, Rini EA, Tully CC, Landrum ML, Zera W, Guymon CH, Yu X, Beckius ML, Cheatle KA, Murray CK, 2013. Staphylococcus aureus colonization of health military service members in the United States and Afghanistan. BMC Infect Dis 13: 325.
-
18.
Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE, 1990. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 43: 608–613.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 348 | 105 | 2 |
| PDF Downloads | 37 | 10 | 1 |
Compliance with Antimalarial Chemoprophylaxis Recommendations for Wounded United States Military Personnel Admitted to a Military Treatment Facility
Malaria chemoprophylaxis is used as a preventive measure in military personnel deployed to malaria-endemic countries. However, limited information is available on compliance with chemoprophylaxis among trauma patients during hospitalization and after discharge. Therefore, we assessed antimalarial primary chemoprophylaxis and presumptive antirelapse therapy (primaquine) compliance among wounded United States military personnel after medical evacuation from Afghanistan (June 2009–August 2011) to Landstuhl Regional Medical Center in Landstuhl, Germany, and then to three U.S. military hospitals. Among admissions at Landstuhl Regional Medical Center, 74% of 2,540 patients were prescribed primary chemoprophylaxis and < 1% were prescribed primaquine. After transfer of 1,331 patients to U.S. hospitals, 93% received primary chemoprophylaxis and 33% received primaquine. Of 751 trauma patients with available post-admission data, 42% received primary chemoprophylaxis for four weeks, 33% received primaquine for 14 days, and 17% received both. These antimalarial chemoprophylaxis prescription rates suggest that improved protocols to continue malaria chemoprophylaxis in accordance with force protection guidelines are needed.
Author Notes
Financial support: The study (IDCRP-024) was supported by the Infectious Disease Clinical Research Program, a Department of Defense program executed through the Uniformed Services University of the Health Sciences; the National Institute of Allergy and Infectious Diseases, National Institute of Health, under Inter-Agency Agreement Y1-AI-5072; and the Department of the Navy under the Wounded, Ill, and Injured Program.
Authors' addresses: Elizabeth A. Rini, Landstuhl Regional Medical Center, CMR 402, Box 1838, APO AE 09180-0019, E-mail: elizabeth.a.rini.mil@mail.mil. Amy C. Weintrob, Walter Reed National Military Medical Center, Bethesda, MD, and Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, E-mail: amy.c.weintrob.ctr@health.mil. David R. Tribble, Faraz Shaikh, Ping Li, Deepak Aggarwal, and M. Leigh Carson, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, E-mails: david.tribble@usuhs.edu, fshaikh@idcrp.org, pli@idcrp.org, daggarwal@idcrp.org, and lcarson@idcrp.org. Bradley A. Lloyd and Clinton K. Murray, San Antonio Military Medical Center, Fort Sam Houston, TX, E-mails: bradley.lloyd@us.af.mil and clinton.k.murray.mil@mail.mil. Tyler E. Warkentien, Walter Reed National Military Medical Center, Bethesda, MD, E-mail: tyler.e.warkentien@health.mil.